MA49971A - Vésicules extracellulaires modifiées et leurs utilisations - Google Patents

Vésicules extracellulaires modifiées et leurs utilisations

Info

Publication number
MA49971A
MA49971A MA049971A MA49971A MA49971A MA 49971 A MA49971 A MA 49971A MA 049971 A MA049971 A MA 049971A MA 49971 A MA49971 A MA 49971A MA 49971 A MA49971 A MA 49971A
Authority
MA
Morocco
Prior art keywords
extracellular vesicles
modified extracellular
modified
vesicles
extracellular
Prior art date
Application number
MA049971A
Other languages
English (en)
Other versions
MA49971B1 (fr
Inventor
Kevin P Dooley
Rane A Harrison
Sonya Haupt
Damian J Houde
John D Kulman
Russell E Mcconnell
Douglas E Williams
Ke Xu
Madeleine Youniss
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70732111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49971(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MA49971A publication Critical patent/MA49971A/fr
Publication of MA49971B1 publication Critical patent/MA49971B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA49971A 2019-04-17 2019-05-22 Vésicules extracellulaires modifiées et leurs utilisations MA49971B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835430P 2019-04-17 2019-04-17
PCT/US2019/033629 WO2020101740A1 (fr) 2018-11-16 2019-05-22 Vésicules extracellulaires modifiées et leurs utilisations

Publications (2)

Publication Number Publication Date
MA49971A true MA49971A (fr) 2020-07-01
MA49971B1 MA49971B1 (fr) 2022-01-31

Family

ID=70732111

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49971A MA49971B1 (fr) 2019-04-17 2019-05-22 Vésicules extracellulaires modifiées et leurs utilisations

Country Status (27)

Country Link
EP (2) EP4059510A1 (fr)
JP (2) JP7538795B2 (fr)
KR (1) KR20210098473A (fr)
CN (1) CN113286603A (fr)
AU (1) AU2019378591A1 (fr)
BR (1) BR112021009231A2 (fr)
CA (1) CA3119720A1 (fr)
CL (1) CL2021001278A1 (fr)
CY (1) CY1124897T1 (fr)
DK (1) DK3672614T3 (fr)
EA (1) EA202191334A1 (fr)
ES (1) ES2907967T3 (fr)
HR (1) HRP20220020T1 (fr)
HU (1) HUE057300T2 (fr)
IL (1) IL283167A (fr)
LT (1) LT3672614T (fr)
MA (1) MA49971B1 (fr)
MD (1) MD3672614T2 (fr)
MX (1) MX2021005636A (fr)
PH (1) PH12021551088A1 (fr)
PL (1) PL3672614T3 (fr)
PT (1) PT3672614T (fr)
RS (1) RS62863B1 (fr)
SG (1) SG11202104956QA (fr)
SI (1) SI3672614T1 (fr)
TW (1) TWI846697B (fr)
WO (1) WO2020101740A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531095A (ja) * 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド エキソソーム及びａａｖの組成物
WO2021003445A1 (fr) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Vésicules extracellulaires ciblant des lymphocytes t et leurs utilisations
JP2022544288A (ja) 2019-08-14 2022-10-17 コディアック バイオサイエンシーズ， インコーポレイテッド ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物
CA3147701A1 (fr) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Vesicules extracellulaires a oligonucleotides antisens ciblant kras
WO2021030776A1 (fr) * 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Constructions de vésicules extracellulaires - aso ciblant stat6
US20230193274A1 (en) 2019-08-14 2023-06-22 Codiak Biosciences, Inc. Extracellular vesicles with stat3-antisense oligonucleotides
US20230103726A1 (en) 2019-09-25 2023-04-06 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20220395465A1 (en) 2019-09-25 2022-12-15 Codiak Biosciences, Inc. Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour
WO2021062058A1 (fr) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Agoniste de sting comprenant des exosomes pour le traitement de troubles neuro-immunologiques
WO2021062057A1 (fr) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Chargement exogène d'exosomes par lyophilisation
MX2022003570A (es) 2019-09-25 2022-07-11 Codiak Biosciences Inc Composiciones de vesícula extracelular.
US20230096378A1 (en) 2020-03-12 2023-03-30 Institute For Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
WO2021184017A1 (fr) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Vésicules extracellulaires pour le traitement de troubles neurologiques
WO2021184021A1 (fr) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Constructions de vésicules extracellulaires - aso ciblant pmp22
WO2021184020A1 (fr) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Méthodes de traitement d'une neuro-inflammation
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
US20240043494A1 (en) * 2020-08-07 2024-02-08 Amicus Therapeutics, Inc. Vesicle Targeting Proteins And Uses Of Same
CA3193107A1 (fr) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Procede de preparation de vesicules extracellulaires
WO2022066883A1 (fr) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Vésicules extracellulaires comprenant des antigènes kras et leurs utilisations
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
GB202015399D0 (en) * 2020-09-29 2020-11-11 Evox Therapeutics Ltd Engineered extracellular vesicles displaying enhanced pharmacokinetics
US20230364127A1 (en) 2020-10-06 2023-11-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
CN112899307A (zh) * 2021-01-28 2021-06-04 苏州大学 GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用
WO2022178147A1 (fr) 2021-02-17 2022-08-25 Codiak Biosciences, Inc. Procédés de chargement de vésicules extracellulaires
EP4294421A2 (fr) * 2021-02-17 2023-12-27 Lonza Sales AG Antagoniste de nlrp3 de vésicule extracellulaire
IL305873A (en) 2021-04-01 2023-11-01 Lonza Sales Ag Extracellular vesicle compositions
CN114057893B (zh) * 2021-04-26 2022-12-30 苏州大学 一种编码线粒体定位的豆蔻酰化多肽及其制备方法与应用
CN117126886A (zh) * 2022-05-20 2023-11-28 谛邈生物科技(北京)有限公司 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用
US20230381226A1 (en) * 2022-05-24 2023-11-30 Shiftbio Inc. Surface-engineered extracellular vesicles and therapeutic uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
SI2254586T1 (sl) 2008-02-22 2015-07-31 Agency For Science, Technology And Research (A*Star) Delci mezenhimske matične celice
FR2950350B1 (fr) 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
EP3164420A4 (fr) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Conjugués ciblés, particules et préparations associées
US10501733B2 (en) * 2015-02-27 2019-12-10 University Of Washington Polypeptide assemblies and methods for the production thereof
AU2016381513A1 (en) 2015-12-30 2018-07-19 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
US10617768B2 (en) * 2016-07-12 2020-04-14 Santa Clara University Engineered exosomes for the delivery of bioactive cargo using transmembrane tetraspanins
WO2018039119A1 (fr) * 2016-08-22 2018-03-01 Codiak Biosciences, Inc. Procédés de suppression de l'administration d'exosomes vers le foie et la rate
WO2018112154A1 (fr) * 2016-12-15 2018-06-21 Codiak Biosciences, Inc. Procédés de mesure d'exosomes à l'aide d'une fluorescence intrinsèque
CN111212632B (zh) 2017-08-25 2024-04-16 隆萨销售股份公司 使用膜蛋白制备治疗性外来体
AU2018367670A1 (en) * 2017-11-17 2020-05-07 Lonza Sales Ag Compositions of engineered exosomes and methods of loading luminal exosomes payloads
WO2020041720A1 (fr) * 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Vésicules extracellulaires ciblant des cellules dendritiques et utilisations associées

Also Published As

Publication number Publication date
TWI846697B (zh) 2024-07-01
MD3672614T2 (ro) 2022-04-30
WO2020101740A9 (fr) 2021-06-10
IL283167A (en) 2021-06-30
LT3672614T (lt) 2022-04-11
BR112021009231A2 (pt) 2021-08-10
TW202038993A (zh) 2020-11-01
ES2907967T3 (es) 2022-04-27
PH12021551088A1 (en) 2022-01-03
CY1124897T1 (el) 2023-01-05
CL2021001278A1 (es) 2022-03-11
SI3672614T1 (sl) 2022-04-29
DK3672614T3 (da) 2022-01-10
HRP20220020T1 (hr) 2022-04-01
CN113286603A (zh) 2021-08-20
RS62863B1 (sr) 2022-02-28
WO2020101740A1 (fr) 2020-05-22
PL3672614T3 (pl) 2022-03-07
EP3672614B1 (fr) 2021-10-06
SG11202104956QA (en) 2021-06-29
AU2019378591A1 (en) 2021-06-17
KR20210098473A (ko) 2021-08-10
PT3672614T (pt) 2022-02-11
MA49971B1 (fr) 2022-01-31
EP3672614A1 (fr) 2020-07-01
CA3119720A1 (fr) 2020-05-22
EP4059510A1 (fr) 2022-09-21
EA202191334A1 (ru) 2022-02-10
JP7538795B2 (ja) 2024-08-22
JP2022513049A (ja) 2022-02-07
MX2021005636A (es) 2021-07-06
JP2024097929A (ja) 2024-07-19
HUE057300T2 (hu) 2022-05-28

Similar Documents

Publication Publication Date Title
MA49971A (fr) Vésicules extracellulaires modifiées et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA55083A (fr) Polyribonucléotides et leurs utilisations cosmétiques
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA55565A (fr) Agents de dégradation de stat et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA50397A (fr) Anticorps anti-tau et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA52365A (fr) Composés et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations